Payment overview · 2025
General Payments
$158.34
8 reported records · 6 companies
Healthcare provider profile · identity verified
John David Rowe, PHYSICIAN ASSISTANT
Physician Assistants & Advanced Practice Nursing Providers|Physician Assistant · WILLACOOCHEE, GA · NPI 1891815924
Verified facts
What the public records show
CMS Open Payments records show John David Rowe, PHYSICIAN ASSISTANT received $158.34 in general payments during 2025 across 8 reported records.
Xeris Pharmaceuticals, Inc. accounted for 33.2% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 8 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Mounjaro.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 58 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported VRAYLAR as an associated drug or biological on 377741 records involving 62704 distinct recipient NPIs. Public Medicare Part D data also shows 20 claims for Vraylar by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported BRILINTA as an associated drug or biological on 993 records involving 512 distinct recipient NPIs. Public Medicare Part D data also shows 32 claims for Brilinta by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 58 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 25 claims for Symbicort by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 116 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 140 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 24 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 90 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 29 claims for Rybelsus by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Xeris Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $52.60 | 33.2% | 3 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $27.81 | 17.6% | 1 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $25.25 | 15.9% | 1 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $22.03 | 13.9% | 1 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $15.33 | 9.7% | 1 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $15.32 | 9.7% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $158.34 | 8 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| GVOKE HYPOPEN Normalized: gvoke hypopen |
Drug | Xeris Pharmaceuticals, Inc. | $28.53 | 2 | 2025 |
Source payment records
|
|||||
| The Cologuard Plus Collection Kit Normalized: the cologuard plus collection kit |
Device | Exact Sciences Corporation | $27.81 | 1 | 2025 |
Source payment records
|
|||||
| VIBERZI Normalized: viberzi |
Drug | ABBVIE INC. | $25.25 | 1 | 2025 |
Source payment records
|
|||||
| KEVEYIS Normalized: keveyis |
Drug | Xeris Pharmaceuticals, Inc. | $24.07 | 1 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $22.03 | 1 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $15.33 | 1 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $15.33 | 1 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $15.32 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 140 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
58 | 16 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | VRAYLAR open payments reported associated product |
CMS Open Payments — General Payments 377741 supporting records · 62704 recipient NPIs · example record 1201352550 |
Vraylar · 2024 Exact normalized brand match · 1 Part D row |
20 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | BRILINTA open payments reported associated product |
CMS Open Payments — General Payments 993 supporting records · 512 recipient NPIs · example record 1206131430 |
Brilinta · 2024 Exact normalized brand match · 1 Part D row |
32 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
58 | 12 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
25 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
116 | 20 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
140 | 22 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
24 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
90 | 20 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
29 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Pantoprazole Sodium | Pantoprazole Sodium | 534 | 101 |
| Atorvastatin Calcium | Atorvastatin Calcium | 524 | 115 |
| Gabapentin | Gabapentin | 446 | 82 |
| Lisinopril | Lisinopril | 345 | 81 |
| Alprazolam | Alprazolam | 336 | 51 |
| Amlodipine Besylate | Amlodipine Besylate | 331 | 76 |
| Furosemide | Furosemide | 228 | 51 |
| Potassium Chloride | Potassium Chloride | 217 | 49 |
| Citalopram Hbr | Citalopram Hydrobromide | 207 | 41 |
| Celecoxib | Celecoxib | 198 | 42 |
| Tamsulosin Hcl | Tamsulosin Hcl | 194 | 40 |
| Omeprazole | Omeprazole | 182 | 36 |
| Carvedilol | Carvedilol | 178 | 38 |
| Clopidogrel | Clopidogrel Bisulfate | 178 | 38 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 176 | 48 |
| Metoprolol Tartrate | Metoprolol Tartrate | 175 | 39 |
| Levothyroxine Sodium | Levothyroxine Sodium | 173 | 32 |
| Methylprednisolone | Methylprednisolone | 167 | 129 |
| Tramadol Hcl | Tramadol Hcl | 162 | 52 |
| Metformin Hcl | Metformin Hcl | 160 | 40 |
| Losartan Potassium | Losartan Potassium | 140 | 40 |
| Mounjaro | Tirzepatide | 140 | 22 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 138 | 33 |
| Amoxicillin | Amoxicillin | 128 | 101 |
| Allopurinol | Allopurinol | 125 | 26 |
| Meloxicam | Meloxicam | 124 | 27 |
| Metoprolol Succinate | Metoprolol Succinate | 120 | 30 |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 118 | 39 |
| Sertraline Hcl | Sertraline Hcl | 117 | 25 |
| Jardiance | Empagliflozin | 116 | 20 |
| Duloxetine Hcl | Duloxetine Hcl | 112 | 15 |
| Azithromycin | Azithromycin | 110 | 85 |
| Lorazepam | Lorazepam | 110 | 23 |
| Zolpidem Tartrate | Zolpidem Tartrate | 110 | 23 |
| Eliquis | Apixaban | 109 | 23 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 108 | 24 |
| Montelukast Sodium | Montelukast Sodium | 106 | 18 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 106 | 15 |
| Tizanidine Hcl | Tizanidine Hcl | 105 | 27 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 104 | 26 |
| Hydrochlorothiazide | Hydrochlorothiazide | 101 | 24 |
| Trazodone Hcl | Trazodone Hcl | 93 | 20 |
| Ozempic | Semaglutide | 90 | 20 |
| Clonazepam | Clonazepam | 84 | 18 |
| Fenofibrate | Fenofibrate | 83 | 24 |
| Baclofen | Baclofen | 82 | 22 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 81 | 18 |
| Pravastatin Sodium | Pravastatin Sodium | 81 | 15 |
| Simvastatin | Simvastatin | 78 | 19 |
| Prednisone | Prednisone | 77 | 30 |
| Famotidine | Famotidine | 76 | 27 |
| Fluticasone Propionate | Fluticasone Propionate | 74 | 37 |
| Ondansetron Hcl | Ondansetron Hcl | 74 | 24 |
| Estradiol | Estradiol | 64 | 14 |
| Clonidine Hcl | Clonidine Hcl | 63 | 15 |
| Cefdinir | Cefdinir | 62 | 48 |
| Farxiga | Dapagliflozin Propanediol | 58 | 12 |
| Linzess | Linaclotide | 58 | 16 |
| Escitalopram Oxalate | Escitalopram Oxalate | 55 | suppressed |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 54 | 22 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 54 | suppressed |
| Glimepiride | Glimepiride | 53 | 15 |
| Memantine Hcl | Memantine Hcl | 53 | 11 |
| Buspirone Hcl | Buspirone Hcl | 51 | 14 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 51 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 50 | suppressed |
| Levetiracetam | Levetiracetam | 50 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 50 | 22 |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 48 | suppressed |
| Myrbetriq | Mirabegron | 47 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 45 | 13 |
| Ropinirole Hcl | Ropinirole Hcl | 45 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 44 | 33 |
| Nystatin | Nystatin | 43 | 20 |
| Breo Ellipta | Fluticasone/Vilanterol | 42 | suppressed |
| Cyanocobalamin Injection | Cyanocobalamin (Vitamin B-12) | 42 | 11 |
| Fenofibrate | Fenofibrate Nanocrystallized | 42 | suppressed |
| Tradjenta | Linagliptin | 42 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 41 | 23 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 38 | 35 |
| Clindamycin Hcl | Clindamycin Hcl | 38 | 30 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 38 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 38 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 36 | suppressed |
| Pregabalin | Pregabalin | 35 | 12 |
| Diazepam | Diazepam | 34 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 33 | suppressed |
| Etodolac | Etodolac | 33 | 19 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 33 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 33 | suppressed |
| Ondansetron Odt | Ondansetron | 33 | 16 |
| Brilinta | Ticagrelor | 32 | suppressed |
| Fluconazole | Fluconazole | 32 | 22 |
| Ezetimibe | Ezetimibe | 31 | suppressed |
| Mometasone Furoate | Mometasone Furoate | 30 | suppressed |
| Temazepam | Temazepam | 30 | suppressed |
| Finasteride | Finasteride | 29 | suppressed |
| Rybelsus | Semaglutide | 29 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 28 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 28 | 14 |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 27 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 27 | suppressed |
| Risperidone | Risperidone | 26 | suppressed |
| Glipizide Er | Glipizide | 25 | suppressed |
| Nifedipine Er | Nifedipine | 25 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 25 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 25 | suppressed |
| Trulicity | Dulaglutide | 24 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 23 | suppressed |
| Glipizide | Glipizide | 23 | suppressed |
| Olanzapine | Olanzapine | 23 | suppressed |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 22 | suppressed |
| Novolog Flexpen | Insulin Aspart | 22 | suppressed |
| Sucralfate | Sucralfate | 22 | suppressed |
| Cephalexin | Cephalexin | 21 | 16 |
| Verapamil Er | Verapamil Hcl | 21 | suppressed |
| Ziprasidone Hcl | Ziprasidone Hcl | 21 | suppressed |
| Lidocaine | Lidocaine | 20 | suppressed |
| Methocarbamol | Methocarbamol | 20 | suppressed |
| Repatha Sureclick | Evolocumab | 20 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 20 | suppressed |
| Vraylar | Cariprazine Hcl | 20 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 19 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 19 | suppressed |
| Chlorthalidone | Chlorthalidone | 19 | suppressed |
| Colchicine | Colchicine | 19 | suppressed |
| Combivent Respimat | Ipratropium/Albuterol Sulfate | 19 | suppressed |
| Valsartan | Valsartan | 19 | suppressed |
| Xarelto | Rivaroxaban | 19 | suppressed |
| Bisoprolol-Hydrochlorothiazide | Bisoprolol/Hydrochlorothiazide | 18 | suppressed |
| Ibuprofen | Ibuprofen | 18 | suppressed |
| Primidone | Primidone | 18 | suppressed |
| Aripiprazole | Aripiprazole | 17 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 17 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 17 | suppressed |
| Januvia | Sitagliptin Phosphate | 17 | suppressed |
| Nitroglycerin | Nitroglycerin | 17 | 11 |
| Cyproheptadine Hcl | Cyproheptadine Hcl | 16 | suppressed |
| Ramelteon | Ramelteon | 16 | suppressed |
| Bupropion Xl | Bupropion Hcl | 15 | suppressed |
| Cefadroxil | Cefadroxil | 15 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 15 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 15 | suppressed |
| Humulin R | Insulin Regular, Human | 15 | suppressed |
| Mupirocin | Mupirocin | 15 | 13 |
| Ofloxacin | Ofloxacin | 15 | 14 |
| Topiramate | Topiramate | 15 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 14 | 12 |
| Dutasteride | Dutasteride | 14 | suppressed |
| Megestrol Acetate | Megestrol Acetate | 14 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 14 | suppressed |
| Rivastigmine | Rivastigmine Tartrate | 14 | suppressed |
| Spiriva Handihaler | Tiotropium Bromide | 14 | suppressed |
| Fosinopril Sodium | Fosinopril Sodium | 13 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 13 | suppressed |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 13 | suppressed |
| Isosorbide Dinitrate | Isosorbide Dinitrate | 13 | suppressed |
| Oseltamivir Phosphate | Oseltamivir Phosphate | 13 | 11 |
| Propranolol Hcl | Propranolol Hcl | 13 | suppressed |
| Indomethacin | Indomethacin | 12 | suppressed |
| Lansoprazole | Lansoprazole | 12 | suppressed |
| Oxcarbazepine | Oxcarbazepine | 12 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 12 | suppressed |
| Vascepa | Icosapent Ethyl | 12 | suppressed |
| Atenolol | Atenolol | 11 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 11 | suppressed |
| Incruse Ellipta | Umeclidinium Bromide | 11 | suppressed |
| Lamotrigine | Lamotrigine | 11 | suppressed |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 11 | suppressed |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 11 | suppressed |
| Repatha Pushtronex | Evolocumab | 11 | suppressed |
| Spironolactone | Spironolactone | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $158.34 · 8 records | Xeris Pharmaceuticals, Inc. | AIRSUPRA, GVOKE HYPOPEN, KEVEYIS, MOUNJARO, The Cologuard Plus Collection Kit, VIBERZI, Wegovy, ZEPBOUND | 10 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Mounjaro play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error